Every 8-K that Insperity, Inc (NSP) has filed with the SEC in the last 24 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 8-K covers material events a company has to report between its quarterly reports, so if you follow NSP and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full NSP filings page.
Insperity reported Q2 2026 results showing early margin recovery progress. Revenue rose 2% to $1,686 million on a 1% decline in average paid worksite employees to 305,764, driven by a 3% increase in revenue per WSEE. Gross profit slipped 3% to $217 million and benefits cost per covered employee increased 5%, but operating expenses fell 8% to $211 million, yielding operating income of $6 million versus a prior-year loss. Net income was $4 million, with diluted EPS of $0.10, compared with a loss of $5 million and $(0.14) per share. Non-GAAP metrics improved, with adjusted EBITDA up 13% to $36 million and adjusted EPS up 31% to $0.34.
For the first half of 2026, revenue grew 2% to $3,581 million while gross profit declined 3% to $519 million. Operating income increased 11% to $68 million, but net income fell 20% to $37 million and diluted EPS decreased 20% to $0.97; adjusted EBITDA rose 4% to $139 million and adjusted EPS declined 10% to $1.64. Management cited pricing and client retention strategies, benefit plan changes, and operating expense control as key contributors to margin recovery, including $16 million year-to-date in Workday partnership costs. Capital returns included repurchase of 172,000 shares for $4 million and dividends of $46 million, with adjusted cash of $95 million and $420 million outstanding under the credit facility at June 30, 2026. Updated 2026 guidance calls for average WSEEs slightly below 2025 and full-year adjusted EPS of $1.88–$2.43 and adjusted EBITDA of $185–$225 million, implying year-over-year increases of 83–136% and 41–72%, respectively.
Insperity, Inc. reported results of its 2026 annual stockholder meeting and an update to its equity compensation plan. Stockholders elected four Class I directors to terms expiring at the 2029 annual meeting and approved, on an advisory basis, the company’s executive compensation program.
Stockholders also approved the Second Amendment to the Insperity, Inc. Incentive Plan, which increases the number of shares of common stock reserved for issuance under the plan by 1,620,000 shares. In addition, Ernst & Young LLP was ratified as the independent registered public accounting firm for the year ending December 31, 2026.
Insperity, Inc. reported Q1 2026 revenue of $1.9 billion, up 2% year over year, while average paid worksite employees (WSEEs) slipped 1% to 303,049. Gross profit declined 3% to $302 million as benefits costs per covered employee rose 5%.
Operating expenses fell 1% to $240 million, including $9 million of restructuring charges tied to workforce realignment, leading to net income of $33 million and diluted EPS of $0.88, both down about 35% from Q1 2025. On a non-GAAP basis, adjusted EBITDA was $103 million and adjusted EPS was $1.31.
Management highlighted progress in a margin recovery plan, supported by new UnitedHealthcare contract terms, pricing and renewal actions, and worksite employee benefit plan changes. Updated 2026 guidance calls for adjusted EPS of $1.60–$2.60 and adjusted EBITDA of $170–$230 million, implying potential improvement from 2025 levels.
Insperity reported weaker fourth-quarter and full-year 2025 results and announced a workforce realignment. Q4 revenues rose 3% to $1.7 billion with average paid worksite employees up 1%, but gross profit fell 21% to $172 million, leading to a net loss of $33 million and adjusted EBITDA of $(13) million.
For 2025, revenues grew 4% to $6.8 billion, while gross profit dropped 14% to $900 million, producing a net loss of $7 million versus a prior-year profit and adjusted EBITDA of $131 million. Management cited elevated healthcare costs as a key headwind.
The Realignment Plan will eliminate about 4% of non-sales roles, with an estimated one-time charge of roughly $9 million in Q1 2026, excluded from non-GAAP metrics. Despite recent losses, 2026 guidance calls for adjusted EPS of $1.69–$2.72 and adjusted EBITDA of $170–$230 million, implying a substantial profitability rebound.
Insperity, Inc. amended its revolving credit facility, increasing the maximum amount it may borrow from $650 million to $750 million and extending the facility’s maturity to December 15, 2028. The amendment also raises the amount by which the facility may be expanded from $700 million to $800 million, giving the company additional committed lending capacity.
The lenders agreed to increase the Maximum Leverage Ratio financial covenant from 3.00 to 3.75 and to revise the definition of EBITDA used in that covenant. Zions Bancorporation, N.A. dba Amegy Bank continues to act as administrative agent under the amended and restated credit agreement.
Insperity (NSP) updated its health benefits arrangement with UnitedHealthcare. On November 3, 2025, a subsidiary signed an amendment that adds expected cost savings starting in 2026 and extends the arrangement through 2028.
The amendment lets Insperity annually choose to limit its responsibility for each participant’s claim costs to $500,000, $750,000, or $1,000,000 per year, revises certain administrative costs payable by the company, and adds volume-based incentives, subject to certain conditions. Other previously disclosed material terms remain unchanged.
Insperity also furnished a press release announcing financial and operating results for the quarter ended September 30, 2025; the release is provided as an exhibit.